Exscientia announces closing of $510.4 million aggregate financing
AI-driven pharmatech company with an office in Oxford, Exscientia plc has announced the closing of its previously announced upsized initial public offering in the United States of 15,927,500 American Depositary Shares (ADSs) representing 15,927,500 ordinary shares, including 2,077,500 ADSs sold pursuant to the full exercise of the underwriters’ previously granted option to purchase additional ADSs.
All ADSs sold in the offering were offered by Exscientia at a public offering price of $22.00 per ADS. The total gross proceeds to Exscientia from the offering were approximately $350.4 million, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by Exscientia. The offering was upsized from the number of shares offered at launch and priced at the top of the price range indicated at launch.
The company also closed the concurrent sale of an additional 7,272,727 ADSs at a price of $22.00 per ADS, for gross proceeds of $160 million, prior to deducting underwriting discounts and commissions payable by Exscientia, in concurrent private placements to SVF II Excel (DE), or Softbank, and the Bill & Melinda Gates Foundation.
Goldman Sachs, Morgan Stanley, BofA Securities, and Barclays Capital acted as joint book-running managers for the offering.
About Exscientia
Exscientia is an AI-driven pharmatech company and the first company to progress AI-designed small molecules into the clinical setting. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Exscientia has offices in Oxford, Miami, Osaka, and Dundee.
